Literature DB >> 12657951

Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas.

Shuho Semba1, Toshiyuki Moriya, Wataru Kimura, Mitsunori Yamakawa.   

Abstract

INTRODUCTION: Akt/PKB promotes cell proliferation and rescues cells from apoptosis. AIM: To evaluate the role of Akt/PKB, a key molecule in phosphatidylinositol 3-OH kinase (PI3K) signaling, during the development of pancreatic duct neoplasias such as intraductal papillary-mucinous tumor (IPMT) and invasive ductal adenocarcinoma (IDAC) of the pancreas. METHODOLOGY AND
RESULTS: In PK-45H pancreatic cancer cells, the growth-inhibitory and apoptosis-inducing effects of LY294002, a PI3K inhibitor, were detected in a concentration-dependent manner, followed by the reduction of phosphorylated Akt levels. Immunohistochemical analyses revealed that frequent overexpression of phosphorylated Akt (Ser473) was detected in 10 (63%) of 16 IPMTs and 14 (70%) of 20 IDACs. It is interesting that the incidence of Akt phosphorylation closely correlated with Ki-67 immunoreactivity and had an inverse association with the number of cases of apoptotic bodies in both IPMT and IDAC. Although there was no good correlation with other clinicopathologic parameters, the two patients with recurrent IPMT had high levels of phosphorylated Akt.
CONCLUSION: Our findings suggest that activation of Akt plays an important role during the progression of these pancreatic duct neoplasias at the early stage. Furthermore, inhibition of the PI3K-Akt/PKB pathway may have therapeutic potential in the treatment of pancreatic duct tumors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12657951     DOI: 10.1097/00006676-200304000-00008

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  17 in total

1.  RNAi knockdown of PIK3CA preferentially inhibits invasion of mutant PIK3CA cells.

Authors:  Xin-Ke Zhou; Sheng-Song Tang; Gao Yi; Min Hou; Jin-Hui Chen; Bo Yang; Ji-Fang Liu; Zhi-Min He
Journal:  World J Gastroenterol       Date:  2011-08-28       Impact factor: 5.742

2.  Ras, PI3K/Akt and senescence: Paradoxes provide clues for pancreatic cancer therapy.

Authors:  Alyssa L Kennedy; Peter D Adams; Jennifer P Morton
Journal:  Small GTPases       Date:  2011-09-01

3.  Biological similarities and differences between pancreatic intraepithelial neoplasias and intraductal papillary mucinous neoplasms.

Authors:  Toshiyuki Moriya; Wataru Kimura; Shuho Semba; Fumiaki Sakurai; Ichiro Hirai; Jinfeng Ma; Akira Fuse; Kunihiko Maeda; Mitsunori Yamakawa
Journal:  Int J Gastrointest Cancer       Date:  2005

4.  Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.

Authors:  Katrina S Pedersen; George P Kim; Nathan R Foster; Andrea Wang-Gillam; Charles Erlichman; Robert R McWilliams
Journal:  Invest New Drugs       Date:  2015-05-08       Impact factor: 3.850

Review 5.  Phosphatidylinositol 3-Kinase: A Link Between Inflammation and Pancreatic Cancer.

Authors:  Chiara Birtolo; Vay Liang W Go; Andrzej Ptasznik; Guido Eibl; Stephen J Pandol
Journal:  Pancreas       Date:  2016-01       Impact factor: 3.327

6.  MIB-1 labeling index, Ki-67, is an indicator of invasive intraductal papillary mucinous neoplasm.

Authors:  Tatsuo Shimura; Yasuhide Kofunato; Ryo Okada; Rei Yashima; Koji Okada; Kenichiro Araki; Yasuo Hosouchi; Hiroyuki Kuwano; Seiichi Takenoshita
Journal:  Mol Clin Oncol       Date:  2016-05-20

7.  Antiproliferative effect of octreotide on gastric cancer cells mediated by inhibition of Akt/PKB and telomerase.

Authors:  Shan Gao; Bao-Ping Yu; Yan Li; Wei-Guo Dong; He-Sheng Luo
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

Review 8.  Biological approaches to therapy of pancreatic cancer.

Authors:  Han Hsi Wong; Nicholas R Lemoine
Journal:  Pancreatology       Date:  2008-08-25       Impact factor: 3.996

9.  Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer.

Authors:  Sanjit K Roy; Rakesh K Srivastava; Sharmila Shankar
Journal:  J Mol Signal       Date:  2010-07-19

10.  Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis.

Authors:  Nhu-An Pham; Joerg Schwock; Vladimir Iakovlev; Greg Pond; David W Hedley; Ming-Sound Tsao
Journal:  BMC Cancer       Date:  2008-02-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.